Drugs / Abenacianine
Abenacianine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06034197 | Feb 2024 → Apr 2025 | colorectal cancer | Stephan Rogalla | Terminated | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT06145048 | Oct 2023 → Oct 2024 | lung cancer | Vergent Bioscience, Inc. | Completed | Met primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT07499674 | Mar → Dec 2026 expected | lung cancer | Vergent Bioscience, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2026-07-28 | Vergent Bioscience, Inc. | Results Vergent Bioscience Announces Publication in The Annals of Surgical Oncology Demonstrating Abenacianine with Intraoperative Molecular Imaging Improved Tumor Visualization During Lung Cancer Surgery vergentbio.com ↗
The results showed the intraoperative molecular imaging agent’s ability to visualize tumors during lung cancer surgery, and the potential to optimize resection by localizing primary and metastatic tumors and minimizing removal of normal tissue. |
| 2025-05-22 | Vergent Bioscience, Inc. | Results Vergent Bioscience Presents Phase 2B VISUALIZE Results Demonstrating Abenacianine for Injection (VGT-309) with Intraoperative Molecular Imaging Improved Tumor Visualization During Lung Surgery vergentbio.com ↗
In the study, abenacianine localized tumors intraoperatively, identified synchronous and occult lesions, helped assess negative margin status, and identified cancer in the lymph nodes enabling a more complete oncologic resection (Abstract #3069). |
| 2025-01-07 | Vergent Bioscience, Inc. | Regulatory Vergent Bioscience Receives FDA Fast Track Designation for Abenacianine for Injection (VGT-309) to Help Surgeons Visualize Tumors in the Lung During Surgery vergentbio.com ↗
Receiving Fast Track designation from the FDA reinforces the potential of abenacianine to address existing deficits in lung cancer surgery by helping surgeons better visualize tumors in the lung during minimally invasive surgical procedures |
| 2024-07-18 | Vergent Bioscience, Inc. | Results Vergent Bioscience Data Published in The Annals of Thoracic Surgery Demonstrate VGT-309 May Help Surgeons Visualize Tumor Tissue in the Lung During Surgery vergentbio.com ↗ |
| 2024-01-28 | Vergent Bioscience, Inc. | Results Vergent Bioscience Presents Phase 2 Data Showing VGT-309 Visualizes Tumors in the Lung During Surgery vergentbio.com ↗
The data demonstrate that VGT-309, the company’s investigational tumor-targeted fluorescent imaging agent, visualizes primary and metastatic tumor tissue in the lung during surgery. |
| 2023-09-11 | Vergent Bioscience, Inc. | Results Vergent Biosciences’ Tumor-Targeted Fluorescent Imaging Agent to Improve Success of Lung Cancer Surgeries vergentbio.com ↗
Findings from the Phase 2 surgical study evaluating VGT-309 suggest the investigational agent could improve surgeons’ ability to see difficult-to-find and previously undetected tumors in real time to help optimize patient outcomes. |
All press releases naming this drug 14 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Abenacianine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07499674 ↗ |
| Known as | Abenacianina | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068084 ↗ |
| Known as | VGT-309 | “Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung” NCT07499674 ↗ |
| Modality | Diagnostic / imaging agent | “Fluorescent Probe, VGT-309” NCT06034197 ↗ |
| Route | Intravenous | “0.32mg/kg IV of VGT-309 given 12-36 hours before surgery” NCT06034197 ↗ |